Recurrence-free survival | Overall survival | |||||
---|---|---|---|---|---|---|
Variable | Median (months) | HR (95% CI) | p Value* | Median (months) | HR (95% CI) | p Value |
Age | ||||||
≤70 | 111 | NR | ||||
>70 | 65.7 | 1.77 (1.11 to 2.82) | 0.028 | 80.0 | 1.99 (1.16 to 3.42) | 0.015 |
Stage | ||||||
1a | 100 | |||||
1b | 75 | 1.43 (0.90 to 2.31) | 0.070 | NR | 1.17 (0.70 to 2.00) | 0.448 |
Sex | ||||||
Female | 93 | NR | ||||
Male | 75 | 1.41 (0.80 to 2.33) | 0.185 | 100 | 1.55 (0.91 to 2.71) | 0.129 |
Histology | ||||||
ADC | 85 | NR | ||||
SCC | 82 | 1.19 (0.75 to 1.92) | 0.412 | NR | 1.15 (0.69 to 1.94) | 0.489 |
Extent of lung resection | ||||||
WR | 71.6 | NR | ||||
Lobectomy | 82 | 1.00 (0.44 to 2.15) | 0.990 | NR | 1.35 (0.55 to 3.25) | 0.557 |
Lymphatic invasion | ||||||
Absent | 82 | NR | ||||
Present | 65.7 | 1.26 (0.73 to 2.39) | 0.439 | NR | 1.42 (0.72 to 2.75) | 0.294 |
Vascular invasion | ||||||
Absent | 82 | NR | ||||
Present | 68 | 1.65 (0.99 to 2.60) | 0.051 | NR | 1.45 (0.80 to 2.51) | 0.186 |
ALDH1A1 | ||||||
Low | NR | NR | ||||
High | 68 | 2.25 (1.22 to 4.00) | 0.005 | 100 | 2.0 (1.03 to 3.93) | 0.027 |
CD133 | ||||||
Low | NR | NR | ||||
High | 64 | 1.22 (0.80 to 1.96) | 0.362 | 100 | 1.43 (0.80 to 2.35) | 0.102 |
Bold indicates statistical significance.
*Log rank test.
ADC, adenocarcinoma; ALDH1A1, aldehyde dehydrogenase 1A1; NR, not reached (median overall survival for these patients had ‘not reached’ during this follow-up period); SCC, squamous cell carcinoma.; WR, Wedge resection.